While anti-CTLA-4 monotherapy at the selected dose and regimen still shows only minimal tumour response, anti-PD-L1 monotherapy and combination therapy suggest that the stronger the neoantigen is, the better the tumour response is. The gene discussed is CD274; the disease is neoplasm.